Category: MUMAK SpotLight

MUMAK SpotLight

MUMAK SpotLight of the week: Five stocks in focus

Eli Lilly, Rheinmetall, Bayer, Palantir, and Revolution Medicines impress with strong developments—but valuation, risks, and chart technicals remain decisive.
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Revolution Medicines with FDA breakthrough. PayPal and Palantir in focus

Revolution Medicines reaches a decisive milestone with the FDA approval of Daraxonrasib. PayPal loses a key short-term price driver as
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: AI and technology weighting continues to rise

Intel, Micron, Palantir, and SpaceX gain weight as the UMBRELLA Strategy continues its rotation toward AI and technology.
Next Update
MUMAK SpotLight

MUMAK Spotlight of the week: SpaceX takes the lead – Technology rotation continues

SpaceX becomes the largest position, Palantir gains weight, and Dell Technologies is newly added to the UMBRELLA Strategy.
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Portfolio rotation strengthens technology weighting

More Intel and Micron, exit from Rheinmetall and TKMS: The UMBRELLA Strategy is clearly shifting its focus toward technology.
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Intel becomes part of the UMBRELLA Strategy

Intel was newly added to the UMBRELLA Strategy, expanding the portfolio's semiconductor positioning. At the same time, Revolution Medicines, Bayer,
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Eli Lilly and Palantir in focus

Eli Lilly strengthens its pipeline, Palantir remains volatile, and Johnson & Johnson gains momentum. The most important developments of the
Next Update
MUMAK SpotLight

MUMAK SpotLight of the Week: Stop-loss signals reshape the UMBRELLA Strategy

UMBRELLA reacts to increased market volatility. Technical signals lead to adjustments and a stronger focus on risk management.
Next Update
MUMAK SpotLight

MUMAK SpotLight of the Week: Apple and Amazon Quarterly Review

Apple and Amazon make a statement – strong quarterly results with differing market reactions
Next Update